<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3003">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122078</url>
  </required_header>
  <id_info>
    <org_study_id>3-2021-0348</org_study_id>
    <nct_id>NCT05122078</nct_id>
  </id_info>
  <brief_title>Effects of Analgesia Nociception Index (ANI)-Guided Analgesia on Postoperative Bowel Function.</brief_title>
  <official_title>Effects of Analgesia Nociception Index (ANI)-Guided Analgesia on Postoperative Bowel Function Recovery in Laparoscopic Colorectal Surgery: A Prospective Randomized-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will examaine the effects of Analgesia Nociception Index (ANI)-guided analgesia&#xD;
      on postoperative bowel function recovery in laparoscopic colorectal surgery. This is a&#xD;
      prospective randomized-controlled study.&#xD;
&#xD;
      Investigators will randomly divide the patients into two groups. In ANI group, remifentanil&#xD;
      infusion rate during anesthesia will be adjusted according to ANI monitoring. In Control&#xD;
      group, remifentanil infusion rate during anesthesia will be adjusted according to the&#xD;
      conventional method of blood pressure and heart rate monitroing. And Investigators will&#xD;
      evalualte the bowel function recovery in both groups after surgery, and compare between the&#xD;
      two groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2021</start_date>
  <completion_date type="Anticipated">October 14, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 14, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single blinded randomized controlled study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patients don't know which group they belong to.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first gas passing from surgery</measure>
    <time_frame>Up to postoperative 2weeks</time_frame>
    <description>Time (hours) to first gas passing from surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to starting fluid intake from surgery</measure>
    <time_frame>up to 2weeks</time_frame>
    <description>Time (hours) to starting oral fluid intake after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to starting soft diet from surgery</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Time (hours) to starting soft diet from surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative opioid consumption</measure>
    <time_frame>during anesthesia</time_frame>
    <description>Total opioid dose administered to the patient during anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative opioid consumption</measure>
    <time_frame>postoperative 6hours, 12hours, 24hours, 36hours, 48hours, 3days, 4days, 5days.(Minimum value: 0, Maximum value: 10, higher score means worse.)</time_frame>
    <description>Total opioid dose administered to the patient after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>postoperative 6hours, 12hours, 24hours, 36hours, 48hours, 3days, 4days, 5days.(Minimum value: 0, Maximum value: 10, higher score means worse.)</time_frame>
    <description>Visual analog scale (VAS) 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea score</measure>
    <time_frame>postoperative 6hours, 12hours, 24hours, 36hours, 48hours, 3days, 4days, 5days</time_frame>
    <description>verbal numerical rating scale 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first rescue analgesics from surgery</measure>
    <time_frame>up to 2weeks</time_frame>
    <description>Time (hours) to first rescue analgesics from surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of vomiting, antiemetic administration</measure>
    <time_frame>up to 2weeks</time_frame>
    <description>Number of vomiting, antiemetic administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to starting ambulation from surgery.</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Time (hours) to starting ambulation from surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoR-15</measure>
    <time_frame>postoperative 1days, 4days</time_frame>
    <description>Score of QoR-15 questionnaire (Quality of Recovery-15) (Minimum value: 0, Maximum value: 150, higher score means better.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics during anesthesia</measure>
    <time_frame>during anesthesia</time_frame>
    <description>hemodynamics (blood pressure, heart rate) during anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Cortisol, Norepinephrine, Epinephrine, IL-6</measure>
    <time_frame>immediately after surgery</time_frame>
    <description>Plasma concentration of Cortisol(mcg/dL), Norepinephrine(pg/mL), Epinephrine(pg/mL), IL-6(pg/mL) immediately after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Postoperative Bowel Function Recovery</condition>
  <arm_group>
    <arm_group_label>ANI group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigator will attach the ANI monitor V2 (MDoloris Medical Systems, Lille, France) to the patient and monitor Analgesia Nociception Index (ANI) during anesthesia. Remifentanil infusion rate is adjusted according to ANI monitoring. The ANI is adjusted to be between 50 and 70.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Remifentanil infusion rate is adjusted according to the conventional method of blood pressure and heart rate monitroing. Blood pressure and heart rate are controlled to be within 20% of baseline. We will not monitor ANI in this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ANI</intervention_name>
    <description>Investigators will attach the ANI monitor V2 (MDoloris Medical Systems, Lille, France) to the patient and monitor Analgesia Nociception Index (ANI) during anesthesia. Remifentanil infusion rate is adjusted according to ANI monitoring. The ANI is adjusted to be between 50 and 70.</description>
    <arm_group_label>ANI group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Remifentanil infusion rate is adjusted according to the conventional method of blood pressure and heart rate monitroing. Blood pressure and heart rate are controlled to be within 20% of baseline. Investigators will not monitor ANI in this group.</description>
    <arm_group_label>ANI group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 19 years who undergo laparoscopic colorectal surgery for colorectal&#xD;
             cancer at Gangnam Severance Hospital, Seoul, South Korea.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Patients undergoing colostomy&#xD;
&#xD;
          -  Patients with history of open abdominal surgery&#xD;
&#xD;
          -  Patients with arrhythmia&#xD;
&#xD;
          -  Patients with pacemaker insertion&#xD;
&#xD;
          -  Patients with history of heart transplantation&#xD;
&#xD;
          -  Patients taking medications that may affect ANI (antimuscarinics, alpha-agonists, beta&#xD;
             blockers)&#xD;
&#xD;
          -  Patients with chronic opioid medication.&#xD;
&#xD;
          -  Cognitive impairment&#xD;
&#xD;
          -  Unable to read consent form (eg illiterate, foreigner, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Young Song</last_name>
    <phone>82-2-2019-3520</phone>
    <email>NEARMYHEART@yuhs.ac</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Myung IL Bae</last_name>
    <phone>82-2-2019-3520</phone>
    <email>BMI87@yuhs.ac</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GangnamSeverance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung IL Bae</last_name>
      <phone>82-2-2019-3520</phone>
      <email>BMI87@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Young Song</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Analgesia Nociception Index (ANI)</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

